Abstract
Methods Liposomes containing both a synthetic MPER peptide (662-LELDKWASLWNWFDITNWLWYIK-684) as a peptide antigen, phosphatidylinositol-4-phosphate (PIP) as a lipid antigen, and monophosphoryl lipid A as a potent adjuvant were used as a formulation to immunize mice. MAbs were then produced and tested for binding to MPER, gp41, and PIP and for the ability to neutralize a replication-competent molecular clone of HIV-1 encoding a primary envelope protein and Renilla luciferase as reporter in human peripheral blood mononuclear cells (PBMC).
Highlights
The purpose of this study was to produce peptide-andlipid-induced murine monoclonal antibodies that replicate the characteristics of the 2F5 and/or 4E10 human antibodies for binding both to the membrane proximal external region (MPER) of gp41 and the adjacent lipid bilayer for neutralizing HIV-1 infection of CD4+ lymphocytes
Liposomes containing both a synthetic MPER peptide (662-LELDKWASLWNWFDITNWLWYIK-684) as a peptide antigen, phosphatidylinositol-4-phosphate (PIP) as a lipid antigen, and monophosphoryl lipid A as a potent adjuvant were used as a formulation to immunize mice
MAbs were produced and tested for binding to MPER, gp41, and PIP and for the ability to neutralize a replication-competent molecular clone of HIV-1 encoding a primary envelope protein and Renilla luciferase as reporter in human peripheral blood mononuclear cells (PBMC)
Summary
Neutralizing antibodies induced by immunization with liposomal gp peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. GR Matyas*1, L Wieczorek, Z Beck, C Ochsenbauer-Jambor, JC Kappes, NL Michael, VR Polonis and CR Alving. Address: 1Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, MD, USA, 2Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, USA and 3University of Alabama at Birmingham/Veterans Affairs Medical Center, Birmingham, USA. Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):P80 doi:10.1186/1742-4690-6-S3-P80. AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
